Navigation Links
The dark path to antisocial personality disorder
Date:2/7/2012

Philadelphia, PA, February 7, 2012 With no lab tests to guide the clinician, psychiatric diagnostics is challenging and controversial. Antisocial personality disorder is defined as "a pervasive pattern of disregard for, and violation of, the rights of others that begins in childhood or early adolescence and continues into adulthood," according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) of the American Psychiatric Association.

DSM-IV provides formal diagnostic criteria for every psychiatric disorder. This process may be guided by rating scales that measure the traits and features associated with a personality disorder. But, until now, no one has studied the dimensional structure associated with the DSM antisocial personality disorder criteria.

Dr. Kenneth Kendler of Virginia Commonwealth University and colleagues examined questionnaire and genetic data from adult twins. They found that the DSM-IV criteria do not reflect a single dimension of liability but rather are influenced by two dimensions of genetic risk reflecting aggressive-disregard and disinhibition.

"When psychiatrists, as clinicians or researchers, think about our psychiatric disorders, we tend to think of them as one thing one kind of disorder a reflection of one underlying dimension of liability," said Dr. Kendler. "This is also true of genetics researchers. We tend to want to identify and then detect 'the' risk genes underlying disorder X or Y."

Kendler added, "What is most interesting about the results of this paper is that they falsify this inherent and rather deeply held assumption. Genetic risk factors for antisocial personality disorder are not one thing. Rather, the disorder, as conceptualized by DSM-IV, reflects two distinct genetic dimensions of risk."

"The findings from this study make sense. The distinction between the two sets of heritable traits contributing to antisocial personality diso
'/>"/>

Contact: Rhiannon Bugno
Biol.Psych@utsouthwestern.edu
214-648-0880
Elsevier
Source:Eurekalert

Page: 1 2

Related biology news :

1. Biography captures Sydney Brenners unflagging scientific curiosity and lively personality
2. Personality predicts political preferences
3. Understanding a cells split personality aids synthetic circuits
4. Cells split personality is a major discovery into neurological diseases
5. Sugar, spice and puppy dog tails: Developing sex-typed personality traits and interests
6. MU researcher identifies possible genetic causes of borderline personality disorder
7. New test spots early signs of inherited metabolic disorders
8. Severe congenital disorder successfully treated in a mouse model for the first time
9. Controlled disorder -- scientists find way to form random molecular patterns
10. Picower: Schizophrenia gene associated with psychiatric disorders and brain development
11. Diagnoses of autism spectrum disorders vary widely across clinics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market announces that its Wocket® smart wallet will ... the Mark", scheduled to air on WABC Radio (am770) in ... . The broadcast air- time for the ... EST. NXT-ID, Inc.,s CEO Gino Pereira will be ...
(Date:6/17/2015)... June 17, 2015  Synaptics Inc. (NASDAQ: ... today announced that Xiaomi, one of the world,s ... ClearPad ® family of capacitive touchscreen ... circuits (DDICs) for its latest smartphones, the Xiaomi ... for full in-cell display solutions and DDICs in ...
(Date:6/16/2015)... -- With the increasing number and severity of data breaches ... recent compromise of Federal employee data from OPM,s ... government agencies. HYPR Corp. announced today that ... has been submitted for testing and approval of Federal ... tamper proofing. The proliferation of security ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... BOSTON It is an accepted ... person,s susceptibility to cancer, and that throughout life, mutations ... increasing the chances of developing cancerous tumors. Now ... Deaconess Medical Center (BIDMC) demonstrates that even subtle changes ...
... of Nottingham have discovered the gene that enables an extraordinary ... including a whole head and brain. Their research ... jigsaw that could one day make the regeneration of old ... The research led by Dr Aziz Aboobaker, a Research ...
... breakthrough for wheat farmers in salt-affected areas, CSIRO researchers ... 25 per cent more grain than the parent variety ... Wales proved that durum wheat varieties containing new salt ... The breakthrough will enable wheat farmers to achieve ...
Cached Biology News:Subtle changes in PTEN tumor suppressor gene can determine cancer susceptibility 2Subtle changes in PTEN tumor suppressor gene can determine cancer susceptibility 3Body builders -- the worms that point the way to understanding tissue regeneration 2
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 /PRNewswire/ ... uses next generation sequencing technology to empower cancer care, ... as chief executive officer. In his expanded role ... for all strategy, business expansion and worldwide operations effective ... as Strand,s chairman and CEO since its founding in ...
(Date:7/1/2015)... InferMed , s ... will augment ... s olutions suite   Elsevier , ... and services, announced today the acquisition of  InferMed , a ... company. InferMed,s Arezzo technology supports clinicians in choosing ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and ... in the first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by ... 2014, this course combines students from both universities and is taught on both ...
(Date:6/30/2015)... June 30, 2015  Today, Americord Registry, one of the ... Andrew Horne , a partner at Kirkland & Ellis LLP, ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are ... Board," says Martin Smithmyer , CEO of Americord. "He ... career that will assist Americord,s growth and vision." ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... to $15.0 Billion; Fourth Quarter 2008 Revenue Flat at ... 38 Percent to $3.90; Fourth Quarter 2008 GAAP Earnings ... Expected to be in the Range of $14.8 to ... in the Range of $4.55 to $4.75THOUSAND OAKS, Calif., ...
... 26 BioLife Solutions, Inc.,(OTC Bulletin Board: ... proprietary,GMP hypothermic storage and cryopreservation media products ... launch of its new quarterly,newsletter BioPreservation Today, ... protocols and processes, to maximize the yield ...
... TAMPA, Fla., Jan. 26 Sirion Therapeutics, Inc., a ... New Drug Application (NDA) for ganciclovir ophthalmic gel, 0.15%, ... and Drug Administration (FDA). Sirion Therapeutics is seeking approval ... ocular disease caused by the herpes simplex virus. The ...
Cached Biology Technology:Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 2Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 3Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 4Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 5Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 6Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 7Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 8Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 9Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 10Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 11Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 12Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 13Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 14Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 15Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 16Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 17Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 18Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 19Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 20Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 21Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 22Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 23Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 24Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 25Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 26Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 27BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 2BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 3Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 3
... Kit, For 100 slides. Immunocytochemistry.Sample types: ... vitro tissue labeling.Recommended cell number: ... 1-2 hours).Store at 2-8 C (except ... Drug Screening & Cellular Assays, Assays ...
... Ideal for isolation and affinity purification ... and peptides. Hydrophobic, monodisperse magnetic particles ... (tosyl) groups, further surface activation is ... antibodies with optimal orientation for affinity ...
... Anti-phospho-Ser/Thr-Pro, MPM-2, agarose conjugate ... sodium azide Quality ... immunoprecipitating mitotic MPM2 antigens ... HeLa cells as shown ...
Calcium Channel alpha 2 delta-2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone 42, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: